Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, 845 Health Sciences Road, Irvine, CA, 92697, USA.
Department of Surgery, University of California, Irvine, 333 City Boulevard West, Suite 1600, Orange, CA, 92868, USA.
Cell Tissue Res. 2019 Nov;378(2):155-162. doi: 10.1007/s00441-019-03046-2. Epub 2019 Jun 17.
In recent years, human umbilical cord blood has emerged as a rich source of stem, stromal and immune cells for cell-based therapy. Among the stem cells from umbilical cord blood, CD45+ multipotent stem cells and CD90+ mesenchymal stem cells have the potential to treat type I diabetes mellitus (T1DM), to correct autoimmune dysfunction and replenish β-cell numbers and function. In this review, we compare the general characteristics of umbilical cord blood-derived multipotent stem cells (UCB-SCs) and umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) and introduce their applications in T1DM. Although there are some differences in surface marker expression between UCB-SCs and UCB-MSCs, the two cell types display similar functions such as suppressing function of stimulated lymphocytes and imparting differentiation potential to insulin-producing cells (IPCs) in the setting of low immunogenicity, thereby providing a promising and safe approach for T1DM therapy.
近年来，人脐带血已成为基于细胞治疗的干细胞、基质细胞和免疫细胞的丰富来源。在脐带血来源的干细胞中，CD45+多能干细胞和 CD90+间充质干细胞具有治疗 1 型糖尿病（T1DM）、纠正自身免疫功能障碍以及补充β细胞数量和功能的潜力。在这篇综述中，我们比较了脐带血来源的多能干细胞（UCB-SCs）和脐带血来源的间充质干细胞（UCB-MSCs）的一般特征，并介绍了它们在 T1DM 中的应用。尽管 UCB-SCs 和 UCB-MSCs 在表面标志物表达上存在一些差异，但这两种细胞类型在低免疫原性的情况下具有相似的功能，如抑制受刺激的淋巴细胞的功能，并赋予产生胰岛素的细胞（IPCs）分化潜能，从而为 T1DM 治疗提供了一种有前途且安全的方法。
